Every year, millions of children worldwide suffer from diarrhea and are at risk of dehydration. S. boulardii I-3799 has showed beneficial effects in children diarrhea management.
Saccharomyces boulardii uses for adults and children diarrhea management is already recommended by doctors and gastroenterologists for decades and is highly documented in the litterature. A meta-analysis designed to compare various nutritional and pharmacologic interventions in reducing diarrhea duration supports towards the use of saccharomyces boulardii in the management of acute children diarrhea.
Children diarrhea management, a clinically proven efficacy for the unique probiotic yeast S. boulardii I-3799
A recent published clinical study, on 100 infants and children 3-36 months of age, has been conducted to assess the safety and efficacy of our unique probiotic yeast strain S.boulardii I-3799 (marketed as Lynside® Pro SCB) in the management of acute diarrhea in children.
During this study, the children were randomly allocated to the probiotic yeast group (receiving S. boulardii I-3799 at a daily dosage of 5 billion CFU twice daily for 5 days) or to the placebo group.
The administration of the unique probiotic yeast demonstrates beneficial effects on the reduction and severity of diarrhea in infants and children.
The results of this study confirms S. boulardii I-3799 supplementation consistency with the scientific literature on saccharomyces boulardii benefits for digestive health.
S. boulardii I-3799, the premium probiotic yeast offering 5 years shelf life
Probiotic yeasts are today well-known for their formulation advantages : shelf stable probiotic, no need to be refrigerated and also a long shelf life that can generally go up to 3 years.
Aware that the formulation with probiotic strains remains a daily challenge for our customers, we worked with our experts in order to bring them a strain that could answer these problems. This is why we can now offer our probiotic yeast Saccharomyces cerevisiae I-3799 with a 5-year shelf life. This extended shelf life reinforces the uniqueness and technical superiority of our strain, reflecting our 160 years of experience in the field of yeasts.
Representing a real opportunity and optimal flexibility for your future food supplements developments, get in touch with us to ask for more details.
DISCOVER ALL OUR LATEST NEWS
Biotic Live: A Successful First Edition Exploring the Power of Probiotic Yeasts
Gnosis by Lesaffre recently hosted the first edition of Biotic Live, a unique event dedicated to exploring the potential of probiotic yeasts. This live session brought together leading experts to present the latest scientific insights and real-world applications of live yeasts in human health.
Redefining Joint Health: Gnosis by Lesaffre Showcases MyCondro™ at CMA Innovation Day
At the recent Innovation Day seminar hosted by Complementary Medicines Australia (CMA), Gnosis by Lesaffre, led by Jose Pinedo Rivera, Product Manager, had the opportunity to present MyCondro™ to an engaged audience of over 250 industry professionals. The session, titled “Keeping Pace with a Changing World: MyCondro™ Disrupts the Chondroitin Sulfate Market,” was well received, sparking interest and conversations around the future of joint health solutions.
Supplementation with Menaquinone-7 (as MenaQ7®) Slows the Progression of Coronary Artery Calcification
The first results from the VitaK-CAC Trial, “Menaquinone-7 Slows Down Progression of Coronary Artery Calcification: A Randomized, Placebo-Controlled Trial,” were presented at the 34th European Meeting on Hypertension and Cardiovascular Protection, organized by the European Society of Hypertension (ESH), held in Milan in May 23–26, 2025.
